Overview Cefprozil 500 mg Tablets Under Fasting Conditions Status: Completed Trial end date: 2003-09-01 Target enrollment: Participant gender: Summary The objective of this study is to compare the relative bioavailability of cefprozil 500 mg tablets (Teva Pharmaceuticals USA) with that of Cefzil® 500 mg tablets (Bristol-Myers Squibb) in healthy, non-smoking adults under fasting conditions. Phase: Phase 1 Details Lead Sponsor: Teva Pharmaceuticals USATreatments: CefprozilCephalosporins